Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply

Executive Summary

Schering-Plough is implementing a prescription tracking program for PEG-Intron to ensure that existing patients will have adequate supply of peginterferon alfa-2b

You may also be interested in...



Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy

Schering-Plough is ending its supply management program for PEG-Intron (peginterferon alfa-2b) based on enhanced production capacity for the hepatitis C agent

Schering PEG-Intron Supply Constraints Resolved; Earnings Forecast Cloudy

Schering-Plough is ending its supply management program for PEG-Intron (peginterferon alfa-2b) based on enhanced production capacity for the hepatitis C agent

Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment

Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe

Related Content

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel